A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar
PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent
HER2-positive breast cancer patients who have no medical history of chemotherapy except
ado-trastuzumab emtansine